Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Obesity Drug Study Points to Effectiveness in Curbing Addictions
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
‘Miracle' drug innovation could see a new Wegovy launch every couple of years, Larry Summer says
Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
STAT7d
Beyond BMI: New report reframes obesity as a spectrum of illness, not just a risk factor
BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...
MM&M9d
Obesity meds to lead charge as pharma sales ride ‘momentum’ into 2025
While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...
After an obesity stumble, BioAge reconnects with its longevity pipeline
The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.
STAT6d
Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...